Cardiology Self-Assessment Program (CardSAP) Book 1: Heart Failure (Cert #L199269)

ACPE Numbers: Various – see listing below
Content Release Date: 5/15/19
Expiration Dates: 11/15/19
Activity Type: Application-based
CE Credits: 13.0 hours 

Accreditation for Pharmacists

The American College of Clinical Pharmacy and American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education. 

Target Audience

The target audience for CARDSAP 2019 Book 1 (Heart Failure) is board certified and advanced-level cardiology pharmacists involved in the management of patients with heart failure, including mechanical and circulatory support, newer therapies, and preserved ejection fraction. 

Activity Overview

This course is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). The course consists of 3 learning modules (see table below) and provides up to 13.0 hours of continuing pharmacy education and/or recertification credit. 

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice. 

These activities are part of the ASHP and ACCP professional development program for BCCP recertification approved by the BPS.  

Recertification Credit*

Board certified pharmacists are eligible to receive up to 13.0 hours of recertification credit for completing this course. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity

ACPE Number

Credit Hours

*Assessment Pass Point

CARDSAP 2019 Book 1 (Heart Failure) - Heart Failure I

0217-9999-19-014-H01-P

5

70%

CARDSAP 2019 Book 1 (Heart Failure) - Heart Failure II

0217-9999-19-015-H01-P

4

73%

CARDSAP 2019 Book 1 (Heart Failure) - Heart Failure III

0217-9999-19-016-H01-P

4

69%


 
 

LEARNING OBJECTIVES 

CARDSAP 2019 Book 1 (Heart Failure) - Heart Failure I
0217-9999-19-014-H01-P

  • Evaluate pharmacotherapy for the patient awaiting left ventricular assist device (LVAD) or heart transplantation (HT).
  • Design optimal therapy for patients receiving extracorporeal membrane oxygenator support.
  • Develop effective thromboprophylactic strategies for patients receiving percutaneous ventricular assist device support.
  • Develop effective treatment for patients with complications of durable LVAD therapy.
  • Design optimal pharmacotherapy for the patient recovering from HT.
  • Justify the pharmacist’s role on transitional care teams.
  • Discuss the evidence broadly supporting the benefit of transitional care programs.
  • Design an effective transitional care program for the patient with heart failure (HF).
  • Evaluate the outcomes associated with HF transitional care programs. 

CARDSAP 2019 Book 1 (Heart Failure) - Heart Failure II
0217-9999-19-015-H01-P

  • Justify the introduction of more recent guideline-directed medical therapy for patients with the diagnosis of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
  • Evaluate the role of sacubitril/valsartan and ivabradine for the management of HFrEF and HFpEF.
  • Assess the role of emerging pharmacotherapeutic agents in the management of comorbid disease states related to the care of patients with heart failure.
  • Evaluate investigational therapies for the management of HFrEF and HFpEF.
  • Distinguish heart failure with preserved ejection fraction (HFpEF) from other heart failure classifications and into HFpEF phenotypes using the results of cardiac imaging, comorbidities, and laboratory findings.
  • Analyze the pathophysiology of HFpEF, relating systemic dysfunctions with cardiac dysfunction.
  • Justify the use of renin-angiotensin-aldosterone antagonists and empagliflozin for a patient case scenario with HFpEF considering comorbidities, symptoms, and ablood pressure and heart rate goal.
  • Analyze the use of pharmacotherapeutics affecting the nitric oxide system in patients with HFpEF.
  • Design pharmacotherapy for HFpEF on the basis of patient presentation, comorbidities, evidence-based or non–evidence-based therapies, and patient outcomes. 

CARDSAP 2019 Book 1 (Heart Failure) - Heart Failure III
0217-9999-19-016-H01-P

  • Define iron deficiency in heart failure (HF).
  • Develop a treatment plan for a patient with HF and iron deficiency.
  • Outline the logistical process for implementing an ambulatory intravenous iron administration within a health system.
  • Evaluate the role of clinically available biomarkers in the pathophysiology of heart failure (HF).
  • Using the latest clinical guidelines and scientific statements, design biomarker-based clinical care for the patient with HF.
  • Develop a therapeutic plan for patients with HF based on biomarker concentrations and patient-specific information.
  • Evaluate published evidence on the impact of select type 2 diabetes mellitus medications on heart failure hospitalizations.
  • Assess the potential for type 2 diabetes mellitus medications to modify heart failure pathophysiology.
  • Given a case, design an appropriate drug regimen for a patient with type 2 diabetes mellitus and heart failure. 

Faculty

William L. Baker, Pharm.D., FCCP, FACC, FAHA
Associate Professor
Department of Pharmacy Practice
University of Connecticut School of Pharmacy
Storrs, Connecticut 

Theodore J. Berei, Pharm.D., MBA, BCPS, BCCP
Clinical Specialist, Advanced Heart Failure
Department of Pharmacy
UW Health
Madison, Wisconsin 

Barry E. Bleske, Pharm.D., FCCP
Professor and Chair
Department of Pharmacy Practice and Administrative Sciences
University of New Mexico
Albuquerque, New Mexico 

Sheryl L. Chow, Pharm.D., FCCP, FAHA, FHFSA
Associate Professor
Department of Pharmacy Practice and Administration
Western University of Health Sciences
Pomona, California 

Zachary L. Cox, Pharm.D., BCPS
Associate Professor
Department of Pharmacy Practice
Lipscomb University College of Pharmacy
Nashville, Tennessee 

Vicki L. Groo, Pharm.D., CHC
Clinical Associate Professor
Department of Pharmacy Practice
Colleges of Pharmacy and Medicine
Clinical Pharmacist
Heart Center
University of Illinois at Chicago
Chicago, Illinois 

Douglas Jennings, Pharm.D., FCCP, FAHA, FACC, FHFSA, BCPS
Associate Professor of Pharmacy
Department of Pharmacy Practice
Long Island University
Clinical Pharmacist – Heart Transplant
Columbia University Irving Medical Center
New York, New York 

Brandon K. Martinez, Pharm.D., BCPS
Cardiovascular Outcomes Research Fellow
Evidence Based Practice Center
School of Pharmacy
Hartford Hospital
University of Connecticut
Hartford, Connecticut 

Jaclynne R. Metayer, Pharm.D.
Clinical Pharmacist
Department of Pharmacy
Maine Medical Center – MaineHealth Cardiology
Portland, Maine

Sharon K. Milfred-LaForest, Pharm.D., FCCP, BCPS
Clinical Pharmacy Specialist, Cardiology and Organ Transplantation
Pharmacy Department
VA Northeast Ohio Healthcare System
Cleveland, Ohio 

Orly Vardeny, Pharm.D., MS, BCPS
Associate Professor
Department of Medicine
Minneapolis VA Center for Care Delivery and Outcomes Research
University of Minnesota
Minneapolis, Minnesota 

Phillip Weeks, Pharm.D., BCPS, BCCP
Clinical Pharmacy Specialist – Advanced Heart Failure and Transplant
Department of Pharmacy
Memorial Hermann – Texas Medical Center
Houston, Texas 

Series Editors

Cynthia A. Jackevicius, Pharm.D., M.Sc., FCCP, FCSHP, FAHA, FCCS, FACC, BCPS-AQ Cardiology, BCCP
Professor, Pharmacy Practice
College of Pharmacy
Western University of Health Sciences
Clinical Pharmacy Specialist, Cardiology
VA Greater Los Angeles Healthcare System
Los Angeles, California 

J. Herbert Patterson, Pharm.D., FCCP, FHFSA
Professor of Pharmacy
Research Professor of Medicine
Executive Vice Chair, Division of Pharmacotherapy and Experimental Therapeutics
UNC Eshelman School of Pharmacy
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina 

Faculty Panel Chair

Robert L. Page II, Pharm.D., MSPH , FCCP, FASHP, FAHA, FHFSA, BCPS-AQ Cardiology, BCGP 

Reviewers

Bassam Atallah, Pharm.D., MS, FHFSA, BCPS-AQ Cardiology
Ohoud Almalki, Pharm.D., BCPS, ASH-CHC, CLS
Anastasia Armbruster, Pharm.D., AACC, BCPS, BCCP
Debra J. Barnette, Pharm.D., FCCP, BCPS, BCACP, CDE
Craig J. Beavers, Pharm.D., BCCP, CACP
Christopher Ensor, Pharm.D., FCCP, FAST, BCPS
Shannon W. Finks, Pharm.D., FCCP, BCPS, BCCP, AHSCP-CHC
Wade Flowers, Pharm.D., BCPS, BCGP
Melanie R. Madorsky, Pharm.D., BCPS, BCCP
Aimon C. Miranda, Pharm.D., BCPS
Robert L. Page II, Pharm.D., MSPH , FCCP, FASHP, FAHA, FHFSA, BCPS-AQ Cardiology, BCGP
Kerry K. Pickworth, Pharm.D., FCCP, BCPS-AQ Cardiology
Christine Price, Pharm.D.
Courtney Shakowski, Pharm.D., BCPS, BCCCP
Matthew A. Silva, Pharm.D., BCPS
Azita H. Talasaz, Pharm.D., BCPS-AQ Cardiology, BCCP
Katie B. Tellor, Pharm.D., FACC, BCPS
Megan Valente, Pharm.D., BCACP
Israa Fadhil Yaseen, BSPharm, FIBMS Clinical Pharmacy, BCPS
Eman El Sayed Younis, Pharm.D., BCPS-AQ Cardiology 

The American College of Clinical Pharmacy, ASHP, and the authors thank the following individuals for their careful review: 

Heart Failure I chapters:
Judy Cheng, Pharm.D., MPH, BCPS (AQ Cardiology)
Mary Wun-Len Lee, Pharm.D., FCCP, BCPS 

Heart Failure II chapters:
H. Gwen Bartlett, Pharm.D., BCPS, BCCCP, BCCP
Emilie L. Karpiuk, Pharm.D., BCPS 

Heart Failure III features:
Lynn Kassel, Pharm.D., BCPS
Ralph H. Raasch, Pharm.D., FCCP, BCPS
Marisel Segarra-Newnham, Pharm.D., MPH, FCCP, BCPS, BCIDP 

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP and the American College of Clinical Pharmacy require that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity. 

Consultancies: Vicki Groo (Regeneron) 

Royalties: Zachary L. Cox (Cumberland Emerging Technologies, Inc.) 

Grants: Barry Bleske (Bristol-Myer Squibb Foundation for Global Medical Impact); Zachary L. Cox (Otuska Pharmaceuticals); Chris Ensor (Amgen); Orly Vardeny (Novartis); Israa Fadhil Yaseen (European Society of Cardiology) 

Honoraria: Zachary L. Cox (Pharmacy Times); Vicki Groo (Bristol-Myers Squibb, Pfizer); Douglas Jennings (Novartis Pharmaceuticals) 

All other planners, presenters, and reviewers of this session report no financial relationships relevant to this activity. 

Methods and CE Requirements

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessments
  • Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 

Development

These activities were developed by ACCP and ASHP.